AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 2.25
(-7.02%)
SEK 2.25
(-7.02%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -29.1 Million SEK | -13.77% |
| 2022 | -25.57 Million SEK | 38.72% |
| 2021 | -41.74 Million SEK | 62.88% |
| 2020 | -112.43 Million SEK | 38.39% |
| 2019 | -182.49 Million SEK | 22.19% |
| 2018 | -234.54 Million SEK | -334.74% |
| 2017 | -53.95 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -43.91 Million SEK | -130.69% |
| 2024 Q1 | -19.03 Million SEK | 34.58% |
| 2023 Q4 | -29.1 Million SEK | 22.32% |
| 2023 Q1 | -53.71 Million SEK | -110.02% |
| 2023 FY | -29.1 Million SEK | -13.77% |
| 2023 Q2 | -45.23 Million SEK | 15.8% |
| 2023 Q3 | -37.46 Million SEK | 17.18% |
| 2022 Q4 | -25.57 Million SEK | 31.19% |
| 2022 Q3 | -37.16 Million SEK | 28.07% |
| 2022 Q2 | -51.67 Million SEK | -101.2% |
| 2022 Q1 | -25.68 Million SEK | 38.47% |
| 2022 FY | -25.57 Million SEK | 38.72% |
| 2021 Q4 | -41.74 Million SEK | 33.4% |
| 2021 FY | -41.74 Million SEK | 62.88% |
| 2021 Q2 | -77.91 Million SEK | 17.26% |
| 2021 Q3 | -62.67 Million SEK | 19.56% |
| 2021 Q1 | -94.16 Million SEK | 16.25% |
| 2020 FY | -112.43 Million SEK | 38.39% |
| 2020 Q4 | -112.43 Million SEK | 15.45% |
| 2020 Q1 | -172.23 Million SEK | 5.63% |
| 2020 Q2 | -153.32 Million SEK | 10.98% |
| 2020 Q3 | -132.97 Million SEK | 13.27% |
| 2019 Q4 | -182.49 Million SEK | 7.29% |
| 2019 Q3 | -196.84 Million SEK | 6.41% |
| 2019 Q2 | -210.31 Million SEK | 5.29% |
| 2019 FY | -182.49 Million SEK | 22.19% |
| 2019 Q1 | -222.05 Million SEK | 5.33% |
| 2018 Q3 | -65.74 Million SEK | 0.0% |
| 2018 FY | -234.54 Million SEK | -334.74% |
| 2018 Q4 | -234.54 Million SEK | -256.75% |
| 2018 Q1 | 53.95 Million SEK | 200.0% |
| 2017 FY | -53.95 Million SEK | 0.0% |
| 2017 Q4 | -53.95 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | -51.216% |
| BioGaia AB (publ) | -1.53 Billion SEK | 98.105% |
| Enzymatica AB (publ) | 17.73 Million SEK | 264.064% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | -409.008% |
| Gabather AB (publ) | -1.11 Million SEK | -2509.865% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 264.546% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 47.866% |
| Nanexa AB (publ) | -61.13 Million SEK | 52.401% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | -90.159% |
| ODI Pharma AB | -2.63 Million SEK | -1003.148% |
| Orexo AB (publ) | 302.8 Million SEK | 109.61% |
| Probi AB (publ) | -275.85 Million SEK | 89.451% |
| Swedencare AB (publ) | 1.42 Billion SEK | 102.047% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 100.149% |
| Toleranzia AB | -17.45 Million SEK | -66.724% |
| Vivesto AB | -1.29 Million SEK | -2140.185% |